376 related articles for article (PubMed ID: 38323033)
1. Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies.
Habibullah M; Jemmieh K; Ouda A; Haider MZ; Malki MI; Elzouki AN
Front Med (Lausanne); 2024; 11():1291501. PubMed ID: 38323033
[TBL] [Abstract][Full Text] [Related]
2. MAFLD and CKD: An Updated Narrative Review.
Mantovani A; Lombardi R; Cattazzo F; Zusi C; Cappelli D; Dalbeni A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806010
[TBL] [Abstract][Full Text] [Related]
3. Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD).
Roeb E
Visc Med; 2021 Aug; 37(4):273-280. PubMed ID: 34540943
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome.
Sinn DH; Kang D; Choi SC; Hong YS; Zhao D; Guallar E; Park Y; Cho J; Gwak GY
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1873-1880.e1. PubMed ID: 36152895
[TBL] [Abstract][Full Text] [Related]
5. Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors.
Huang XJ; Yin M; Zhou BQ; Tan XY; Xia YQ; Qin CX
World J Hepatol; 2023 Aug; 15(8):985-1000. PubMed ID: 37701916
[TBL] [Abstract][Full Text] [Related]
6. The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: A systematic review and meta-analysis.
Agustanti N; Soetedjo NNM; Damara FA; Iryaningrum MR; Permana H; Bestari MB; Supriyadi R
Diabetes Metab Syndr; 2023 May; 17(5):102780. PubMed ID: 37201293
[TBL] [Abstract][Full Text] [Related]
7. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
Cheng WC; Chen HF; Cheng HC; Li CY
Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
[TBL] [Abstract][Full Text] [Related]
8. Fibrosis-4 Index Score Predicts Concomitant Coronary Artery Diseases Across the Spectrum of Fatty Liver Disease.
McNally BB; Rangan P; Wijarnpreecha K; Fallon MB
Dig Dis Sci; 2023 Sep; 68(9):3765-3773. PubMed ID: 37392337
[TBL] [Abstract][Full Text] [Related]
9. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
[TBL] [Abstract][Full Text] [Related]
10. Innate immunity and nonalcoholic fatty liver disease.
Kountouras J; Kazakos E; Kyrailidi F; Polyzos SA; Zavos C; Arapoglou S; Boziki M; Mouratidou MC; Tzitiridou-Chatzopoulou M; Chatzopoulos D; Doulberis M; Papaefthymiou A; Vardaka E
Ann Gastroenterol; 2023; 36(3):244-256. PubMed ID: 37144011
[TBL] [Abstract][Full Text] [Related]
11. From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-New Terminology in Pediatric Patients as a Step in Good Scientific Direction?
Flisiak-Jackiewicz M; Bobrus-Chociej A; Wasilewska N; Lebensztejn DM
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33804296
[TBL] [Abstract][Full Text] [Related]
12. Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease.
Dai YN; Xu CF; Pan HY; Huang HJ; Chen MJ; Li YM; Yu CH
World J Clin Cases; 2022 May; 10(13):4097-4109. PubMed ID: 35665109
[TBL] [Abstract][Full Text] [Related]
13. MAFLD and risk of CKD.
Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
[TBL] [Abstract][Full Text] [Related]
14. Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study.
Jung CY; Koh HB; Park KH; Joo YS; Kim HW; Ahn SH; Park JT; Kim SU
Diabetes Metab; 2022 Jul; 48(4):101344. PubMed ID: 35346856
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name.
Ng CH; Huang DQ; Nguyen MH
Clin Mol Hepatol; 2022 Oct; 28(4):790-801. PubMed ID: 35545437
[TBL] [Abstract][Full Text] [Related]
16. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Kang SH; Cho Y; Jeong SW; Kim SU; Lee JW;
Clin Mol Hepatol; 2021 Apr; 27(2):257-269. PubMed ID: 33751877
[TBL] [Abstract][Full Text] [Related]
17. Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD).
Méndez-Sánchez N; Díaz-Orozco LE
Med Sci Monit; 2021 Jul; 27():e933860. PubMed ID: 34248137
[TBL] [Abstract][Full Text] [Related]
18. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease.
Sun DQ; Targher G; Byrne CD; Wheeler DC; Wong VW; Fan JG; Tilg H; Yuan WJ; Wanner C; Gao X; Long MT; Kanbay M; Nguyen MH; Navaneethan SD; Yilmaz Y; Huang Y; Gani RA; Marzuillo P; Boursier J; Zhang H; Jung CY; Chai J; Valenti L; Papatheodoridis G; Musso G; Wong YJ; El-Kassas M; Méndez-Sánchez N; Sookoian S; Pavlides M; Duseja A; Holleboom AG; Shi J; Chan WK; Fouad Y; Yang J; Treeprasertsuk S; Cortez-Pinto H; Hamaguchi M; Romero-Gomez M; Al Mahtab M; Ocama P; Nakajima A; Dai C; Eslam M; Wei L; George J; Zheng MH
Hepatobiliary Surg Nutr; 2023 Jun; 12(3):386-403. PubMed ID: 37351121
[TBL] [Abstract][Full Text] [Related]
19. Metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease from clinical to pathological characteristics: a multi-center cross-sectional study in real world.
Li Y; Dai C; Ruan Y; Yang H; Zeng H; Huang R; Wang J; Dai M; Hao J; Wang L; Li J; Yan X; Lu Z; Ji F
Postgrad Med J; 2024 Apr; 100(1183):319-326. PubMed ID: 38272486
[TBL] [Abstract][Full Text] [Related]
20. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.
Liang Y; Chen H; Liu Y; Hou X; Wei L; Bao Y; Yang C; Zong G; Wu J; Jia W
J Clin Endocrinol Metab; 2022 Jan; 107(1):88-97. PubMed ID: 34508601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]